Intranasal insulin alleviates cognitive deficits and amyloid pathology in young adult APPswe/PS1dE9 mice

Aging Cell

Volumn 15, Issue 5, 2016, Pages 893-902

  Mao, Yan Fang ^a   Guo, Zhangyu ^a   Zheng, Tingting ^a   Jiang, Yasi ^a   Yan, Yaping ^a   Yin, Xinzhen ^a   Chen, Yanxing ^a   Zhang, Baorong ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Alzheimer's disease; amyloid pathology; APP processing; APP PS1; insulin signaling

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; INSULIN; STRESS ACTIVATED PROTEIN KINASE;

ADULT; ALZHEIMER DISEASE; AMYLOID NEUROPATHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME ACTIVATION; HIPPOCAMPUS; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN TREATMENT; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; YOUNG ADULT;

EID: 84986208231     PISSN: 14749718     EISSN: 14749726     Source Type: Journal    
DOI: 10.1111/acel.12498     Document Type: Article

References (44)

1. Arold S, Sullivan P, Bilousova T, Teng E, Miller CA, Poon WW, Vinters HV, Cornwell LB, Saing T, Cole GM (2012) Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer's disease and apoE TR mouse cortex. Acta Neuropathol. 123, 39–52.
2. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel J-C, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease–associated Aβ oligomers. J. Clin. Investig. 122, 1339.
3. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC (2001) BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nat. Neurosci. 4, 233–234.
4. Chen Y, Zhao Y, C-l Dai, Liang Z, Run X, Iqbal K, Liu F, Gong C-X (2014) Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Aβ level and microglia activation in the brains of 3xTg-AD mice. Exp. Neurol. 261, 610–619.
5. Chua L-M, Lim M-L, Chong P-R, Hu ZP, Cheung NS, Wong B-S (2011) Impaired neuronal insulin signaling precedes Aβ42 accumulation in female AβPPsw/PS1ΔE9 mice. J. Alzheimers Dis. 29, 783–791.
6. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 69, 29–38.
7. De Felice F, Vieira M, Saraiva L, Figueroa-Villar J, Garcia-Abreu J, Liu R, Chang L, Klein W, Ferreira S (2004) Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization. FASEB J. 18, 1366.
8. Deelen J, Beekman M, Uh HW, Helmer Q, Kuningas M, Christiansen L, Kremer D, van der Breggen R, Suchiman HED, Lakenberg N (2011) Genome-wide association study identifies a single major locus contributing to survival into old age; the APOE locus revisited. Aging Cell 10, 686–698.
9. Deng W, Aimone JB, Gage FH (2010) New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? Nat. Rev. Neurosci. 11, 339–350.
10. Ferguson SA, Sarkar S, Schmued LC (2013) Longitudinal behavioral changes in the APP/PS1 transgenic Alzheimer's disease model. Behav. Brain Res. 242, 125–134.
11. Ferreira ST, Clarke JR, Bomfim TR, De Felice FG (2014) Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. Alzheimers Dement. 10, S76–S83.
12. Gallagher J, Minogue A, Lynch M (2013) Impaired performance of female APP/PS1 mice in the Morris water maze is coupled with increased Aβ accumulation and microglial activation. Neurodegener. Dis. 11, 33–41.
13. Gourmaud S, Paquet C, Dumurgier J, Pace C, Bouras C, Gray F, Laplanche J-L, Meurs EF, Mouton-Liger F, Hugon J (2015) Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline. J. Psychiatry Neurosci. 40, 151.
14. Hamilton A, Holscher C (2012) The effect of ageing on neurogenesis and oxidative stress in the APP swe/PS1 deltaE9 mouse model of Alzheimer's disease. Brain Res. 1449, 83–93.
15. Hanson LR, Frey WH II (2007) Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. J. Neuroimmune Pharmacol. 2, 81–86.
16. Hanson LR, Fine JM, Svitak AL, Faltesek KA (2013) Intranasal administration of CNS therapeutics to awake mice. J. Vis. Exp., e4440.
17. Harris-White M, Frautschy S (2005) Low density lipoprotein receptor-related proteins (LRPs), Alzheimer's and cognition. Curr. Drug Targets CNS Neurol. Disord. 4, 469–480.
18. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204–1222.
19. Joseph D'Ercole A, Ye P (2008) Expanding the mind: insulin-like growth factor I and brain development. Endocrinology 149, 5958–5962.
20. Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, Rumbaugh G (2010) Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 35, 870–880.
21. Kim J, Jiang H, Park S, Eltorai AE, Stewart FR, Yoon H, Basak JM, Finn MB, Holtzman DM (2011) Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. J. Neurosci. 31, 18007–18012.
22. Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, Kremmer E, Roßner S, Lichtenthaler SF (2010) ADAM10 is the physiologically relevant, constitutive α-secretase of the amyloid precursor protein in primary neurons. EMBO J. 29, 3020–3032.
23. Lalonde R, Kim H, Fukuchi K (2004) Exploratory activity, anxiety, and motor coordination in bigenic APPswe+ PS1/ΔE9 mice. Neurosci. Lett. 369, 156–161.
24. Lee M-S, Kao S-C, Lemere CA, Xia W, Tseng H-C, Zhou Y, Neve R, Ahlijanian MK, Tsai L-H (2003) APP processing is regulated by cytoplasmic phosphorylation. J. Cell Biol. 163, 83–95.
25. Marks DR, Tucker K, Cavallin MA, Mast TG, Fadool DA (2009) Awake intranasal insulin delivery modifies protein complexes and alters memory, anxiety, and olfactory behaviors. J. Neurosci. 29, 6734–6751.
26. Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 31, 224–243.
27. O'Kusky JR, Ye P, D'Ercole AJ (2000) Insulin-like growth factor-I promotes neurogenesis and synaptogenesis in the hippocampal dentate gyrus during postnatal development. J. Neurosci. 20, 8435–8442.
28. Pan X, Gong N, Zhao J, Yu Z, Gu F, Chen J, Sun X, Zhao L, Yu M, Xu Z (2010) Powerful beneficial effects of benfotiamine on cognitive impairment and β-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain. 133, 1342–1351.
29. Reiserer R, Harrison F, Syverud D, McDonald M (2007) Impaired spatial learning in the APPSwe+ PSEN1ΔE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav. 6, 54–65.
30. Salameh TS, Bullock KM, Hujoel IA, Niehoff ML, Wolden-Hanson T, Kim J, Morley JE, Farr SA, Banks WA (2015) Central nervous system delivery of intranasal insulin: mechanisms of uptake and effects on cognition. J. Alzheimers Dis., 47, 715–728.
31. Shoji M, Iwakami N, Takeuchi S, Waragai M, Suzuki M, Kanazawa I, Lippa CF, Ono S, Okazawa H (2000) JNK activation is associated with intracellular β-amyloid accumulation. Mol. Brain Res. 85, 221–233.
32. Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, Gage FH, Verma IM, Masliah E (2005) Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat. Neurosci. 8, 1343–1349.
33. Talbot K, Wang H-Y, Kazi H, Han L-Y, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Investig. 122, 1316.
34. Troy CM, Rabacchi SA, Xu Z, Maroney AC, Connors TJ, Shelanski ML, Greene LA (2001) β-Amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J. Neurochem. 77, 157–164.
35. White MF (2006) Regulating insulin signaling and β-cell function through IRS proteins This paper is one of a selection of papers published in this Special Issue, entitled Second Messengers and Phosphoproteins-12th International Conference. Can. J. Physiol. Pharmacol. 84, 725–737.
36. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B (1994) Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 145, 1030.
37. Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R (2002) Alzheimer's amyloid peptides compete for insulin binding to the insulin receptor. J. Neurosci. 22, RC221.
38. Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, Gonzales E, Holtzman DM, Lee J-M (2009) Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J. Neurosci. 29, 10706–10714.
39. Yu J-T, Tan L, Hardy J (2014) Apolipoprotein e in Alzheimer's disease: an update. Annu. Rev. Neurosci. 37, 79–100.
40. Zhao C, Deng W, Gage FH (2008a) Mechanisms and functional implications of adult neurogenesis. Cell 132, 645–660.
41. Zhao W-Q, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL (2008b) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 22, 246–260.
42. Zhou Q, Wang M, Du Y, Zhang W, Bai M, Zhang Z, Li Z, Miao J (2015) Inhibition of c-Jun N-terminal kinase activation reverses Alzheimer disease phenotypes in APPswe/PS1dE9 mice. Ann. Neurol. 77, 637–654.
43. Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H, Smith MA (2001) Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J. Neurochem. 76, 435–441.
44. Zick Y (2005) Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Sci. Signal. 2005, pe4.